Trametinib, a new protein kinase inhibitor for BRAF V600 positive melanoma

Mekinist (trametinib) can be used as monotherapy or in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

by Moriam Adetokunboh-Ajala
Prior to treatment with trametinib, patients must be tested to confirm their tumour has a BRAF V600 mutation. | SCIENCE PHOTO LIBRARY
Prior to treatment with trametinib, patients must be tested to confirm their tumour has a BRAF V600 mutation. | SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package